NCT01142518View on ClinicalTrials.gov

An Observational Study of Multiple Sclerosis (MS) Patients Starting or Restarting Baseline Treatment With Interferon Beta 1a After the Use of Escalation Treatment With Mitoxantrone

CompletedOBSERVATIONAL

Enrollment

Participants

Timeline

Start Date

July 31, 2005

Primary Completion Date

March 31, 2009

Study Completion Date

March 31, 2009

Conditions

Relapsing-Remitting Multiple Sclerosis

Interventions

DRUG

Interferon beta 1a

Interferon beta 1a was administered at a dose of 44 μg x 3 as a subcutaneous self-injection.

All Listed Sponsors

lead

Merck KGaA, Darmstadt, Germany

INDUSTRY

NCT01142518 - An Observational Study of Multiple Sclerosis (MS) Patients Starting or Restarting Baseline Treatment With Interferon Beta 1a After the Use of Escalation Treatment With Mitoxantrone | Biotech Hunter | Biotech Hunter